|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1995-12-15
|
|
pubmed:abstractText |
1. We studied the inhibitory effect of pituitary adenylate cyclase activating polypeptide (PACAP 1-27) on the increase in total pulmonary resistance (RL) caused either by allergen or histamine in anaesthetized, ventilated guinea-pigs. 2. PACAP 1-27 given via i.v. infusion (0.045-4.5 nmol kg-1 min-1) dose-dependently reduced the increase in RL caused by inhaled ovalbumin and histamine. At the highest dose, PACAP 1-27 prevented the increase in RL caused by ovalbumin and histamine completely. Infusion of PACAP 1-27 and the beta 2-adrenoceptor agonist, salbutamol (0.045-4.5 nmol kg-1 min-1) inhibited the increase in RL similarly, but salbutamol increased the heart rate more than PACAP 1-27. 3. PACAP 1-27 and salbutamol given via inhaled aerosol (0.1 mM, 20 breaths) significantly reduced the increase in RL caused by histamine infused i.v., whereas aerosolised sterile saline did not. Both PACAP 1-27 and salbutamol caused bronchodilator effects within 1 min of drug inhalation and these effects remained throughout the 20 min of study. 4. Because PACAP 1-27 produced significant bronchodilatation and rapid onset of sustained action in vivo and without pronounced cardiovascular side effects, we conclude that this peptide may have therapeutic potential as a bronchodilator.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-1313597,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-1333743,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-1811273,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-2463981,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-3064106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-6465669,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-7692775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-7932181,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-8346490,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-8381977,
http://linkedlifedata.com/resource/pubmed/commentcorrection/7582520-8499774
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-1188
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
115
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
913-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:7582520-Adenylate Cyclase,
pubmed-meshheading:7582520-Animals,
pubmed-meshheading:7582520-Bronchodilator Agents,
pubmed-meshheading:7582520-Dose-Response Relationship, Drug,
pubmed-meshheading:7582520-Guinea Pigs,
pubmed-meshheading:7582520-Histamine,
pubmed-meshheading:7582520-Injections, Intravenous,
pubmed-meshheading:7582520-Male,
pubmed-meshheading:7582520-Neuropeptides,
pubmed-meshheading:7582520-Ovalbumin,
pubmed-meshheading:7582520-Pituitary Adenylate Cyclase-Activating Polypeptide,
pubmed-meshheading:7582520-Pituitary Gland,
pubmed-meshheading:7582520-Pulmonary Circulation,
pubmed-meshheading:7582520-Time Factors,
pubmed-meshheading:7582520-Vasodilator Agents
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Inhibition of bronchoconstriction by pituitary adenylate cyclase activating polypeptide (PACAP 1-27) in guinea-pigs in vivo.
|
|
pubmed:affiliation |
Cardiovascular Research Institute, University of California, San Francisco 94143-0130, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
